As a trusted leader in the immunotherapy field, the Society for Immunotherapy of Cancer (SITC) collaborates with other groups to contribute toward high-quality educational programming on tumor immunology and cancer immunotherapy.
Through these educational partnerships, SITC is able to bring high quality, timely cancer immunotherapy information to learners around the world from a variety of backgrounds including scientists, academicians, researchers, clinicians, government representatives and industry leaders.
SITC offers various levels of support for the programs below, such as sharing information about unique programs, providing expert speakers to enhance programming and organizing immunotherapy sessions at relevant association meetings.
If you'd like to get in touch with the society to discuss Collaborative Education Programs, please email the SITC Live Education Department at Education@sitcancer.org.
Be Part of the Breakthrough at the Charles River World Congress on Animal Models in Drug Discovery & Development. Boston | September 26-27, 2017 http://breakthroughs.criver.com/index.html
Use of mAb-based immunotherapies has resulted in major improvements in treatment of B-cell neoplasms, but patients can relapse, succumbing to the disease. An alternative approach that destroys tumor cells including cancer stem cells is, thus, needed urgently. ...
According to the cited pharma company document within, out of Hemel Hempstead, England, May 10, 2017, Dinutuximab beta, originally developed by the Vienna-based biotech company Apeiron Biologics for neuroblastoma, was previously available in Europe under ...
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients. In this exclusive interview with Oncology Central, ...
Chimeric antigen receptor (CAR) T cell therapy shows effectiveness against hematologic malignancies, particularly, against B-cell acute lymphoblastic leukemia in clinical trials. But is also to be enhanced for solid cancers. CARs can increase tumor specificity ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org